In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Chiron Halts Menjugate Meningococcal Vaccine Program After Pivotal Trials

This article was originally published in The Pink Sheet Daily

Executive Summary

Phase III trials were “successfully concluded,” but there are no plans to file a BLA for the meningococcal C conjugate vaccine due to limited commercial viability, Chiron says. The company plans to begin Phase III trials for its quadravalent meningococcal vaccine in 2005.

You may also be interested in...

Three Congressional Flu Hearings Planned For Next Week

The Senate Special Committee on Aging and the House Energy & Commerce and Government Reform Committees will hold hearings to discuss flu vaccine supply. FDA Acting Commissioner Lester Crawford and NIAID Director Anthony Fauci are expected to be among the witnesses.

Menactra Approval Awaits Final Manufacturing Clearance

Sanofi-Aventis says it is prepared to produce a limited supply of the meningococcal conjugate vaccine soon after licensure. To meet expanded demand, the company is constructing a new Menactra manufacturing facility that will be fully operational in two to three years.

NME Slowdown Shows Market Pressure On Me-Toos, Not FDA Caution – Lutter

DURHAM, N.C. - The decline in FDA's tally of new molecular entity approvals stems from fewer approvals of non-innovative products in recent years, while approvals of truly innovative products has largely held steady, according to FDA Deputy Commissioner for Policy, Planning and Preparedness Randall Lutter





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts